Terms ending in 2041
Every in-force patent on Sandoz AG's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,970,450 | Multi-Component Crystals of an Orally Available Hif Prolyl Hydroxylase Inhibitor In force · High confidence | Sandoz AG | In force | High confidence | |
| US 11,273,128 | Elagolix Formulation In force · High confidence | Sandoz AG | In force | High confidence | |
| US 12,043,590 | Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid In force · High confidence | Sandoz AG | In force | High confidence | |
| US 12,605,506 | Automatic Drug Delivery Device In force · High confidence | Novartis AG | In force | High confidence | |
| US 12,161,843 | Automatic Drug Delivery Device In force · High confidence | Novartis AG | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Sandoz AG.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.